The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.

ABSTRACT: Despite major advances in the understanding of the molecular mechanisms that underpin the development of diabetic kidney disease, current best practice still leaves a significant proportion of patients with end-stage kidney disease requiring renal replacement therapy. This is on a background of an increasing diabetes epidemic worldwide. Although kidney failure is a major cause of morbidity the main cause of death remains cardiovascular in nature. Hence, diabetic therapies which are both "cardio-renal" protective seem the logical way forward. In this review, we discuss the dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4inh), which are glucose-lowering agents used clinically and their role in diabetic kidney disease with specific focus on renoprotection and surrogate markers of cardiovascular

SUBMITTER: Panchapakesan U 

PROVIDER: S-EPMC4551869 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature